CWChanyuan Wu

Chanyuan Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chanyuan Wu has a total of 83 co-authors. Here are the top co-authors by number of shared publications:

  • Qian Wang

    Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH); Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education , Beijing , China

    8 shared publications
  • Jiuliang Zhao

    Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH); Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education , Beijing , China

    7 shared publications
  • Mengtao Li

    Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China

    7 shared publications
  • Mengtao Li

    Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100032, China

    6 shared publications
  • Xiaofeng Zeng

    Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH); Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education , Beijing , China

    5 shared publications
  • Xiaofeng Zeng

    Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China

    5 shared publications

Latest Publications

  • Open Access

    Microarray analysis of microrna expression in peripheral blood mononuclear cells of patients with polymyositis and dermatomyositis

    by Jia Shi, Shuang Zhou, Jiuliang Zhao, Dong Xu, Hui Huang, Mengtao Li, Xinping Tian, Linrong He, Chanyuan Wu, Qian Wang, et al.

    Background and Objectives: MicroRNAs (miRNAs) represent a new class of biomarkers in the context of connective tissue disorders. The miRNA expression profiles in peripheral blood mononuclear cells (PBMCs) of patients with polymyositis (PM) and dermatomyositis (DM) have not been fully elucidated. The objective is to investigate miRNAs expression profile in PBMCs of patients with PM/DM. Methods: Microarray technology was used to identify differentially expressed miRNAs in PBMCs obtained from 6 untreated PM/DM patients and 3 healthy controls (HCs). TaqMan-based stem-loop real-time PCR detection was used for validation in a cohort of 34 PM/DM patients and 20 HCs. Results: Microarray analysis revealed 38 differentially expressed miRNAs (24 up-regulated and 14 down-regulated) in PM/DM patients compared to HCs. Four miRNAs (miR-320a, miR-335-3p, miR-34a-5p and miR-454-3p) were chosen for real-time PCR validation. The expression of miR-34a-5p was significantly upregulated in PM/DM group (P < 0.05). In subgroup analysis, miR-34a-5p was significantly upregulated in interstitial lung disease (ILD) group and DM group (P < 0.001). The level of SIRT1, a validated target of miR-34a, was significantly lower in PBMCs of PM/DM patients compared with HCs. Conclusions: MiR-34a-5p may potentially participate in the pathogenesis of PM/DM through SIRT1, and may serve as a potential new biomarker for PM/DM-ILD.


  • Comment on: The diagnostic value of sST2 for myocardial fibrosis in idiopathic inflammatory myopathies in subclinical stage of cardiac involvement

    by Lixi Zhang, Liying Peng, Shuang Zhou, Chanyuan Wu, Qian Wang, Mengtao Li

    Lixi Zhang, Liying Peng, Shuang Zhou, Chanyuan Wu, Qian Wang, Mengtao Li; Comment on: The diagnostic value of sST2 for myocardial fibrosis in idiopathic inflamm

  • Open Access

    Non-apoptotic programmed cell deaths in diabetic pulmonary dysfunction: the new side of advanced glycation end products

    by Yimin Dai, Shuang Zhou, Lin Qiao, Zhao Peng, Jiuliang Zhao, Dong Xu, Chanyuan Wu, Mengtao Li, Xiaofeng Zeng, Qian Wang

    Diabetes mellitus (DM) is a chronic metabolic disorder that affects multiple organs and systems, including the pulmonary system. Pulmonary dysfunction in DM patients has been observed and studied for years, but the underlying mechanisms have not been fully understood. In addition to traditional mechanisms such as the production and accumulation of advanced glycation end products (AGEs), angiopathy, tissue glycation, oxidative stress, and systemic inflammation, recent studies have focused on programmed cell deaths (PCDs), especially the non-apoptotic ones, in diabetic pulmonary dysfunction. Non-apoptotic PCDs (NAPCDs) including autophagic cell death, necroptosis, pyroptosis, ferroptosis, and copper-induced cell death have been found to have certain correlations with diabetes and relevant complications. The AGE–AGE receptor (RAGE) axis not only plays an important role in the traditional pathogenesis of diabetes lung disease but also plays an important role in non-apoptotic cell death. In this review, we summarize novel studies about the roles of non-apoptotic PCDs in diabetic pulmonary dysfunction and focus on their interactions with the AGE–RAGE axis.


  • Open Access

    LP-038 Infection in systemic lupus erythematosus-associated diffuse alveolar hemorrhage: a potential key to improve outcomes

    by Mucong Li, Wei Bai, Yanhong Wang, Lan Song, Shangzhu Zhang, Jiuliang Zhao, Chanyuan Wu, Mengtao Li, Xinping Tian, Xiaofeng Zeng

    Background This study aimed to investigate the clinical characteristics, outcomes, and risk factors of patients with a rare but fatal manifestation of systemic lupus erythematosus (SLE), diffusive alveolar hemorrhage (DAH), stratified by infection status in a national representative cohort. Methods This single-center retrospective study included 124 consecutive patients with SLE-DAH in a tertiary care center between 2006 to 2021. The diagnosis of DAH was made based on a comprehensive evaluation of clinical manifestations, laboratory and radiologic findings, and bronchoalveolar lavage. Demographics, clinical features, and survival curves were compared between patients with bacterial, non-bacterial, and non-infection groups. Univariate and multivariate logistic regression analysis were performed to determine the factors independently associated with bacterial infection in SLE-DAH. Results Fifty-eight patients with SLE-DAH developed bacterial infection after DAH occurrence, thirty-two patients developed fungal and/or viral infection, and thirty-four patients were categorized as non-infection. The bacterial infection group have a worse prognosis (OR 3.059, 95%CI 1.469–6.369, p=0.002) compared with the other two groups, with a mortality rate of 60.3% within 180 days after DAH occurrence. Factors independently associated with bacterial infections in SLE-DAH included hematuria (OR 4.523, 95%CI 1.068–19.155, p=0.040), hemoglobin drop in the first 24 hours after DAH occurred (OR 1.056, 95%CI 1.001–1.115, p=0.049), and anti-Smith antibody (OR 0.167, 95%CI 0.052–0.535, p=0.003). Glucocorticoid pulse therapy and cyclophosphamide were administered in more than 50% of patients regardless of their infectious status. According to clinical experience at our hospital and in previous studies, we recommended a comprehensive management algorithm for SLE-DAH based on infection stratification. Conclusions Infection, especially bacterial infection, is a severe complication and prognostic factor of SLE-DAH. Comprehensive management strategies, including diagnosis, evaluation, treatment, and monitoring, based on infection stratification may fundamentally improve outcomes of patients with SLE-DAH. Comprehensive management algorithm for SLE-DAH. SLE, systemic lupus erythematosus; DAH, diffusive alveolar hemorrhage; HgB, hemoglobin; BALF, bronchoalveolar lavage fluid; Anti-Sm: anti-Smith antibodies; CTX, cyclophosphamide.

  • Huge water-balloons in the belly: multiple pancreatic pseudocysts in systemic lupus erythematosus

    by Mucong Li, Shuang Zhou, Yang Chen, Jiuliang Zhao, Chanyuan Wu, Mengtao Li

    A 28-year-old woman presented with recurrent epigastric pain and abdominal distention for 6 months. Her symptoms first occurred on the first day of admission due to SLE flare (fever, polyarthritis, anaemia, leukocytopenia, proteinuria, low C3, positive tests on antinuclear, anti-double-stranded DNA, anti-Smith and anti-cardiolipin antibodies), when no treatment was initiated. Elevated blood amylase and CT ( Fig. 1A) indicated acute pancreatitis and other common causes were excluded. Thrombotic microangiopathy (TMA) was then suspected because of renal, neuropsychiatric and haematological involvements. However, abdominal distention and peripancreatic effusions perpetuated though SLE, TMA and secondary infection remitted after using glucocorticoid, immunosuppressive agents, plasma exchange and supportive therapies. Therefore, drainage was performed a month before this presentation and CT ( Fig. 1B) showed improvement. During this admission, emergency drainage was performed due to reappearing ascites. Analysis of chylous ascites identified extremely elevated amylase and lipase with Enterococcus faecium as pathogen. Massive ascites were encapsulated with a fistula connected to the newly emerged pseudocyst ( Fig. 1C and D). Drainage was not removed until radiographic remission 7 months later ( Fig. 1E). SLE flare and abdominal symptoms have not occurred up to the last follow-up 41 months after this admission. This case illustrates SLE-associated acute pancreatitis can present with atypical features [ 1, 2] and prolonged courses due to ‘add-on’ effects of SLE flare, infection, coagulopathy (thrombocytopenic purpura, antiphospholipid syndrome) and medication. Therefore, a tailored management strategy is required.

  • Infection in systemic lupus erythematosus-associated diffuse alveolar hemorrhage: a potential key to improve outcomes

    by Mucong Li, Wei Bai, Yanhong Wang, Lan Song, Shangzhu Zhang, Jiuliang Zhao, Chanyuan Wu, Mengtao Li, Xinping Tian, Xiaofeng Zeng

    Objectives This study aimed to investigate the clinical characteristics, outcomes, and associated factors of patients with systemic lupus erythematosus-associated diffusive alveolar hemorrhage (SLE-DAH) stratified by infection status in a national representative cohort. Methods This single-center retrospective study included 124 consecutive patients with SLE-DAH in a tertiary care center between 2006 and 2021. The diagnosis of DAH was made based on a comprehensive evaluation of clinical manifestations, laboratory and radiologic findings, and bronchoalveolar lavage. Demographics, clinical features, and survival curves were compared between patients with bacterial, non-bacterial, and non-infection groups. Univariate and multivariate logistic regression analyses were performed to determine the factors independently associated with bacterial infection in SLE-DAH. Results Fifty-eight patients with SLE-DAH developed bacterial infection after DAH occurrence, thirty-two patients developed fungal and/or viral infection, and thirty-four patients were categorized as non-infection. The bacterial infection group have a worse prognosis (OR 3.059, 95%CI 1.469–6.369, p = 0.002) compared with the other two groups, with a mortality rate of 60.3% within 180 days after DAH occurrence. Factors independently associated with bacterial infections in SLE-DAH included hematuria (OR 4.523, 95%CI 1.068–19.155, p = 0.040), hemoglobin drop in the first 24 h after DAH occurred (OR 1.056, 95%CI 1.001–1.115, p = 0.049), and anti-Smith antibody (OR 0.167, 95%CI 0.052–0.535, p = 0.003). Glucocorticoid pulse therapy and cyclophosphamide were administered in more than 50% of patients regardless of their infectious status. According to clinical experience at our hospital and in previous studies, we recommended a comprehensive management algorithm for SLE-DAH based on infection stratification. Conclusion Infection, especially bacterial infection, is a severe complication and prognostic factor of SLE-DAH. Comprehensive management strategies, including diagnosis, evaluation, treatment, and monitoring, based on infection stratification may fundamentally improve outcomes of patients with SLE-DAH. Key Points • Bacterial infection is an important, but neglected, prognosis factor of systemic lupus erythematosus (SLE)-associated diffusive alveolar hemorrhage (DAH). • Hematuria, hemoglobin drop, and anti-Smith antibody can independently predict bacterial infections in SLE-DAH. • We put forward a comprehensive management algorithm based on infection stratification for SLE-DAH.


  • Open Access

    Annual Direct Cost and Cost-Drivers of Systemic Lupus Erythematosus: A Multi-Center Cross-Sectional Study from CSTAR Registry

    by Haiyan Wang, Mengtao Li, Kaiwen Zou, Yilin Wang, Qiaoling Jia, Li Wang, Jiuliang Zhao, Chanyuan Wu, Qian Wang, Xinping Tian, et al.

    Background: To estimate the annual direct costs and cost-drivers associated with systemic lupus erythematosus (SLE) patients in China. Methods: A multi-center, cross-sectional study was conducted based on the CSTAR registry. The information on demography and expenditures for outpatient and inpatient visits due to SLE were collected using online questionnaires. These patients’ medical records were from the database of the Chinese Rheumatology Information System (CRIS). The average direct costs and 95% confidence interval were estimated using the bootstrap method with 1000 bootstrap samples by resampling with replacement. The cost-drivers were identified using multivariate regression models. Results: A total of 1778 SLE patients from 101 hospitals participated in our study, with 92.58% as females, a mean age of 33.8 years old, a median duration of SLE of 4.9 years, 63.8% in an active disease state, 77.3% with two organs or more damaged, and 8.3% using biologics as treatment. The average annual direct cost per patient was estimated at CNY 29,727, which approximates to 86% for direct medical costs. For moderate to severe disease activities, the use of biologics, hospitalization, treatment of moderate or high dose glucocorticoids, and peripheral vascular, cardiovascular, and/or renal system involvements were found to substantially increase the direct costs, while health insurance slightly decreased the direct costs of SLE. Conclusions: This study provided reliable insight into financial pressures on individual SLE patients in China. The efforts focusing on preventing flare occurrences and limiting disease progression were recommended to further reduce the direct cost of SLE.


  • Open Access

    Successful treatment of a patient with rheumatoid arthritis and comorbid multicentric reticulohistiocytosis

    by Fei Chang, Chanyuan Wu, Tao Wang, Qian Wang

    Multicentric reticulohistiocytosis (MRH) is a rare disease of unknown pathogenesis, characterized by skin histiocytosis and destructive arthritis. The present study describes a 53-year-old woman who presented with rheumatoid arthritis (RA) and MRH, which is a clinically rare entity. Diagnosis of MRH was based on nodule pathology. Meanwhile, the patient had typical arthritis, was positive for serum anti-cyclic citrullinated peptide (anti-CCP) antibodies and synovitis confirmed by joint ultrasound, and was diagnosed with RA. Her symptoms resolved with glucocorticoids and methotrexate.

  • Open Access

    Programmed Cell Death Pathways in the Pathogenesis of Idiopathic Inflammatory Myopathies

    by Jia Shi, Mingwei Tang, Shuang Zhou, Dong Xu, Jiuliang Zhao, Chanyuan Wu, Qian Wang, Xinping Tian, Mengtao Li, Xiaofeng Zeng

    Idiopathic inflammatory myopathy (IIM) is a heterogeneous group of acquired, autoimmune muscle diseases characterized by muscle inflammation and extramuscular involvements. Present literatures have revealed that dysregulated cell death in combination with impaired elimination of dead cells contribute to the release of autoantigens, damage-associated molecular patterns (DAMPs) and inflammatory cytokines, and result in immune responses and tissue damages in autoimmune diseases, including IIMs. This review summarizes the roles of various forms of programmed cell death pathways in the pathogenesis of IIMs and provides evidence for potential therapeutic targets.